Immunoglobulin Light-chain Amyloidosis clinical trials

The registry lists 239 studies for Immunoglobulin Light-chain Amyloidosis across more than 10 countries. 63 are recruiting or about to start. 115 of them are mainly about Immunoglobulin Light-chain Amyloidosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Immunoglobulin Light-chain Amyloidosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 121
Recruiting: 49
Terminated: 23
Active, not recruiting: 13
Withdrawn: 10
Not yet recruiting: 10

Phase

Phase 2: 94
Phase 1: 64
Phase 3: 30
Early Phase 1: 5
Phase 4: 1

Where

United States: 151
Italy: 33
China: 29
Germany: 21
France: 21
United Kingdom: 19

Who runs them

Fondazione IRCCS Policlinico San Matteo di Pavia (13) · Boston Medical Center (12) · Mayo Clinic (8) · Memorial Sloan Kettering Cancer Center (8) · Barbara Ann Karmanos Cancer Institute (7) · National Cancer Institute (NCI) (7) · SWOG Cancer Research Network (6) · Prothena Biosciences Ltd. (6)

What is being tested here

Drugs under test in Immunoglobulin Light-chain Amyloidosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Teclistamab	5	0	6
Dexamethasone	4	3	30
Bortezomib	4	2	14
Daratumumab	4	1	10
Pomalidomide	3	0	8
Cyclophosphamide	2	1	12
Belantamab mafodotin	2	0	3
Elranatamab	2	0	2
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F	2	0	2
Daratumumab and Hyaluronidase-fihj	2	1	2

Drug classes tested here Corticosteroids 4 open · Proteasome inhibitors 4 open · Alkylating agents 2 open · Antimetabolites 8 · Calcineurin inhibitors 3

Coming up

6phase 3 studies under way

16studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Dec 2026Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis · Nexcella Inc.
Dec 2026A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis · University of Tennessee Graduate School of Medicine
Dec 2026Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis · Jin Lu, MD
Dec 2026The Italian Transthyretin Amyloidosis Web-Network · Fondazione IRCCS Policlinico San Matteo di Pavia
Dec 2026Teclistamab in Previously Treated AL Amyloidosis · Peking Union Medical College Hospital
Jan 2027Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab · Weill Medical College of Cornell University
Jan 2027Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis · Peking Union Medical College Hospital
Mar 2027Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis · University of Texas Southwestern Medical Center
Apr 2027DapagliFLOzin in Renal AL Amyloidosis (FLORAL) · Barbara Ann Karmanos Cancer Institute
May 2027A Registry of AL Amyloidosis (ReAL) · Fondazione IRCCS Policlinico San Matteo di Pavia

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger. 3 (6%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (10%) take healthy volunteers.

Recruiting studies that take each age, of 49
Age	Women	Men
10	3 (6%)	3 (6%)
18	45 (92%)	45 (92%)
30	46 (94%)	46 (94%)
40	48 (98%)	48 (98%)
50	48 (98%)	48 (98%)
65	49 (100%)	49 (100%)
75	48 (98%)	48 (98%)
85	45 (92%)	45 (92%)

Across all 239 studies, recruiting or not: 16% stop at 75 or younger and 5% at 65; 14% take children; <1% are for women only and <1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Immunoglobulin Light-chain Amyloidosis studies take

Of 31 phase 2 interventional studies under Immunoglobulin Light-chain Amyloidosis, half reached primary completion within 58 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	58 mo43–89 · 31 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered1

Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisOct 28, 2026NCT07901725

Studies

Recruiting first, then most recently updated. Showing 50 of 239. Browse all 239 → or search them.